Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Antiandrogen strategies in prostate cancer: reconstitution of oestrogen receptor beta].

Thelen P, Strauss A, Stettner M, Kaulfuss S, Ringert RH, Loertzer H.

Urologe A. 2010 Sep;49(9):1124, 1126-8, 1130. doi: 10.1007/s00120-010-2370-0. German.

PMID:
20725712
2.

Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.

Martin SK, Kyprianou N.

Adv Cancer Res. 2015;127:123-58. doi: 10.1016/bs.acr.2015.03.001. Epub 2015 Mar 29. Review.

PMID:
26093899
3.

A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.

Kuruma H, Matsumoto H, Shiota M, Bishop J, Lamoureux F, Thomas C, Briere D, Los G, Gleave M, Fanjul A, Zoubeidi A.

Mol Cancer Ther. 2013 May;12(5):567-76. doi: 10.1158/1535-7163.MCT-12-0798. Epub 2013 Mar 14.

4.

Up-Regulation of LAT1 during Antiandrogen Therapy Contributes to Progression in Prostate Cancer Cells.

Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, Kanai Y, Ichikawa T.

J Urol. 2016 May;195(5):1588-97. doi: 10.1016/j.juro.2015.11.071. Epub 2015 Dec 9.

PMID:
26682754
5.

Abiraterone and novel antiandrogens: overcoming castration resistance in prostate cancer.

Ferraldeschi R, Pezaro C, Karavasilis V, de Bono J.

Annu Rev Med. 2013;64:1-13. doi: 10.1146/annurev-med-121211-091605. Epub 2012 Sep 27. Review.

PMID:
23020876
6.

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.

Rehman Y, Rosenberg JE.

Drug Des Devel Ther. 2012;6:13-8. doi: 10.2147/DDDT.S15850. Epub 2012 Jan 16. Review.

7.

Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer.

Eichholz A, Ferraldeschi R, Attard G, de Bono JS.

Mol Cell Endocrinol. 2012 Sep 5;360(1-2):68-75. doi: 10.1016/j.mce.2011.09.038. Epub 2011 Oct 1. Review.

PMID:
21986558
8.

Androgens, antiandrogens and androgen receptor abnormalities.

Kuil CW, Brinkmann AO.

Eur Urol. 1996;29 Suppl 2:78-82. Review.

PMID:
8717468
9.

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.

PMID:
18635218
10.

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.

Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL.

Proc Natl Acad Sci U S A. 2011 Jun 7;108(23):9578-82. doi: 10.1073/pnas.1106383108. Epub 2011 May 23.

11.

Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL.

Science. 2009 May 8;324(5928):787-90. doi: 10.1126/science.1168175. Epub 2009 Apr 9.

12.

Androgen receptor antagonists for prostate cancer therapy.

Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, Claessens F.

Endocr Relat Cancer. 2014 Aug;21(4):T105-18. doi: 10.1530/ERC-13-0545. Epub 2014 Mar 17. Review.

13.

Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.

Maggiolini M, Recchia AG, Carpino A, Vivacqua A, Fasanella G, Rago V, Pezzi V, Briand PA, Picard D, Andò S.

J Mol Endocrinol. 2004 Jun;32(3):777-91.

PMID:
15171712
14.

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN, Jones RJ, Goodman OB, Mainwaring PN, Sternberg CN, Efstathiou E, Gagnon DD, Rothman M, Hao Y, Liu CS, Kheoh TS, Haqq CM, Scher HI, de Bono JS.

Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9.

PMID:
23142059
15.

Overcoming castration resistance in prostate cancer.

Tsao CK, Small AC, Galsky MD, Oh WK.

Curr Opin Urol. 2012 May;22(3):167-74. doi: 10.1097/MOU.0b013e3283523b8b. Review.

PMID:
22472508
16.

The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.

Courtney KD, Taplin ME.

Curr Opin Oncol. 2012 May;24(3):272-7. doi: 10.1097/CCO.0b013e328351059d. Review.

PMID:
22327837
17.

Antiandrogens in combination with LH-RH agonists in prostate cancer.

Raynaud JP.

Am J Clin Oncol. 1988;11 Suppl 2:S132-47. Review.

PMID:
3071951
18.

Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer.

Griffiths K, Morton MS, Nicholson RI.

Eur Urol. 1997;32 Suppl 3:24-40. Review.

PMID:
9267783
19.

Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.

Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.

BJU Int. 2012 Oct;110(8):1149-55. doi: 10.1111/j.1464-410X.2012.10959.x. Epub 2012 Feb 28.

20.

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.

Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.

Cochrane Database Syst Rev. 2014 Jun 30;(6):CD009266. doi: 10.1002/14651858.CD009266.pub2. Review.

PMID:
24979481

Supplemental Content

Support Center